Avid Bioservices Inc (CDMO)

[biopharm]

David Carbone was a key KOL that knew the value of PS Targeting IP and gave some very helpful information to Biothera regarding Bavituximab and the anti-PS platform

I wonder what the late Paul Carbone would say about his son that stays quiet like Dr Jedd Wolchok and the others ....what oath is taken when one becomes an MD? I though it was something about bringing the best treatments forward and don't sell out the patients just because some John Springs Stafford friends want to make money and delay PS Targeting

_____

It is time for the FDA to allow 3D imaging from several various technologies to support the MOA of certain drugs and let us SEE the targeting of flipped PS that occurs BEFORE other protein pathways shift back to safety and restore ones immune system to optimal levels before any other toxic drugs wants to be shoved down the FDA approval line

Everyone best wake up and realize that there was a reason why CDMO Avid is being granted big contracts

I guess it they push the price up north enough, everyone becomes Wolchok like and shuts the hell up

_______

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

Inventor

Nandita Bose
Keith GORDEN
Anissa S H. Chan
Steven LEONARDO
Jeremy GRAFF
Xiaohong Qiu
Takashi KANGAS
Kathryn A. FRASER
Adria BYKOWSKI JONAS
Nadine OTTOSON
Ross Fulton

Current Assignee: Biothera Inc


DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

....the invention may also be carried out with complement activating immune suppression-relieving agents. One example may be bavituximab.

https://patents.google.com/patent/US10111901

______________

June 1, 2019

Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

https://www.biothera.com/biothera-pharmaceuticals-presents-clinical-data-from-phase-2-study-evaluating-the-combination-of-imprime-pgg-and-mercks-keytruda-in-triple-negative-breast-cancer-at-2019-asco-annual-meeting/